Phase 2 Brain Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You have been diagnosed with a specific type of brain tumor called glioblastoma (with particular molecular features: IDH wild-type and MGMT promoter methylated), confirmed by a tissue sample, and the tumor has come back for the first time and been surgically removed or biopsied.
• Before your surgery or biopsy, scans showed at least one measurable tumor that was clearly visible and large enough to be measured in two directions (at least 10mm each way).
• You previously received the standard first treatment for glioblastoma, which includes chemotherapy with temozolomide combined with radiation therapy.
• You have not received any other treatment for the recurrent tumor beyond surgery or biopsy.
• You are 18 years of age or older.
• You are well enough to carry out most daily activities (a doctor will assess this using a standard scale).
• Your blood counts are at healthy enough levels — including white blood cells, platelets, and hemoglobin (confirm with trial site).
• Your liver and kidney function are within acceptable ranges (confirm with trial site).
• If you are living with HIV, you are on effective treatment and your virus levels are undetectable within the past 6 months.
• If you have or have had hepatitis B, your virus levels must be undetectable while on appropriate treatment.
• If you have had hepatitis C, you must have been successfully treated and cured, or currently be on treatment with undetectable virus levels.
• If you have or have had another type of cancer, you may still be eligible as long as it is unlikely to interfere with this trial's treatment or results.
• If you have a history of heart problems or have received treatments that affect the heart, your heart function must meet a minimum standard on a recognised heart health scale (confirm with trial site).
• You are willing and able to use effective contraception during the study and for a set period after treatment ends (180 days for women; 90 days for men), because the study drugs may harm an unborn baby.
• You are able to understand and sign a consent form, or have a legal representative who can do so on your behalf.

Who may not be able to join:

• Your body has not fully recovered from side effects of previous chemotherapy.
• You still have significant side effects (above a minor level) from any previous cancer treatment, apart from hair loss.
• You are currently taking part in another clinical trial involving an experimental treatment.
• You have previously been treated with a drug called bevacizumab.
• You have had a serious allergic reaction to drugs chemically similar to selinexor or temozolomide (the two study drugs).
• You have had a hypersensitivity reaction to a drug called dacarbazine, as it is processed by the body in a similar way to temozolomide.
• You have another serious illness that is not currently under control.
• You are pregnant, as the study drugs could harm an unborn baby.
• You are breastfeeding, as the study drugs may pass to a nursing infant; breastfeeding is not allowed during treatment and for 7 days after the last dose.
• You are hospitalised with severe COVID-19 and are aged 75 or older, or have certain high-risk indicators identified by specific medical tests (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.